Sun turnin' 'round with graceful motion
We're setting off with soft explosion
Bound for a star with fiery oceans
It's so very lonely, you're ten thousand light years from home.
Time to bang the table again on NNVC?
I found this succinct analysis of NNVC's prospects over on the iHub NNVC forum and wanted to make sure everyone understood where this company is on its path to becoming a major anti-viral pharmaceutical company:
Let's look at possible valuations for NNVC:
Currently completing animal studies and known to be entering pre-IND tox package:The poster, "Dr. Feelgood," is a long-time shareholder and supporter of the company. He deals in facts and logical deductions therefrom. Assigning a modest PE of 20 to the above numbers suggests a share price of $300. If their stuff works, the company may be worth $300 a share, just based on three out of 6-8 indications from their drug platform.
Hiv-Cide for treatment of AIDS-- potential market $3 to $5 billion
Dengue-Cide treatment for Dengue and in particular DHF-- potential market over $1 billion
HSV-1 and HSV-2 treatment for genital Herpes-- potential market well over $1 billion
Once one indication is approved, the other 2 indications will be less than a year from market or revenue.
So, $1 billion divided by 200 million shares o/s worse case scenario leaves $5 earnings for each indication.
That sure looks like a share price over $2 to me.
If you disagree with the above you really, really don't know anything about NNVC, it's market potential, its technology, or the likelihood of approval.
Does their stuff work? It's early, but reputable, respected viral researchers are chiming in with a resounding, "Yes!" from their laboratories.
Yet the stock is mired in a painful 50% decline from it's May 3, 2010 high of $2.64. I am awaiting a Trend Model BUY Signal before banging the table for NNVC shares, much the way I did last October when it dipped under $0.50. An interim BUY on the 240_minute Trend Model comes in today at $1.38, a Daily BUY at $1.45.
What does the company have to say?
In response to a question to Dr. Seymour about the daily fluctuations in stock price:
"We know from its historical performance that major events have had a significant impact on the price. If I'm asked, I suggest that people not obsessively watch the price but check it only every now and then. In fact, I subscribe to a service that gives me real-time quotes with the number of shares bought and sold. The sheer manipulation of the stock by the market makers drove me crazy so I followed my own advice and stopped watching. People should be more interested in the fact that we've never had a failure...some minor glitches perhaps, all corrected, but that's just Mother Nature having fun with those who attempt to divine her closely guarded secrets. Progress of the Company is all that one should focus on."
---EUGENE SEYMOUR, MD, MPH
Chief Executive Officer